Home
overview

The threat of antibiotic- resistant microbes poses one of the biggest economic and health threats in our time, as microbes are becoming more resistant and fewer drugs are passing clinical trials successfully.

Moreover, the increase in global migration accelerates the spread as we have seen from Mers and Ebola viruses, as well as overconsumption and hospital acquired infections.

Thus, our 18th year in hosting Superbugs and Superdrugs continues to address the core challenges in the industry from: Investment, R&D to hospital hygiene, and consumer engagement and review current strategies.

We’re now seeing strong leaderships and collaborations to fund research and investment from the likes of: The Welcome Trust, IMI, and BARDA who are invited to share their funding strategies to strengthen the antiobiotics pipeline.
 

Our 2016 program will feature new updates on global collaborations and funding schemes: Case study reviews of strategies designed to best adapt with emerging threats and changing economies.

In addition, further insight into mechanism of infectious activity as well as robust screening and modelling tools to mimic bacterial structure will add fresh insight in R&D and drug development
 

Key topics new for 2016 include:

• Extending portfolio partnerships to strengthen the antibiotic
• Expansion of the COMBACTE project and European clinical trial network
• Smart antimicrobials to combat HAI’s and inhibit biofilm-derived infections
• Harnessing genomics and host –pathogen relationships to control of viral infections
 

   

ABAC Therapeutics; Absynth Biologics; Achaogen; Actelion; Anacor Pharmaceuticals Inc; Angelini; BARDA; Basilea Pharmaceutica; BIOASTER; Biopharm Insight; Cambridge University; Da Volterra; Debiopharm; Discuva; Drugs for Neglected Diseases initiative (DNDi); EFPIA; Emergent Biosolutions; Emergent BioSolutions Inc.; European Commision; Evotec; F. Hoffmann-La Roche; GlaxoSmithkline; Grifols America Inc; Health Protection Agency; Index Ventures; KWS BioTest; MGB Biopharma; MHRA; Novartis; Office of Health Economics (OHE); PharmaConsulting; Pherecydes; Pherecydes Pharma; Plant Bioscience Limited; Public Health England; Redx Pharma; Selcia; Spero Therapeutics; Sponsored By Scottish Executive; Tiber Creek Partners; TranScrip Partners; Umm Al-Qura University; University of North Texas Health Science Center; Vifor (International) Ltd; Voyage tour; Wellcome Trust;

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Richard Bax

Richard Bax, Senior Partner, TranScrip Partners

  • Global territorial differences in research and investment
  • Boosting surveillance efforts in high-threat areas
  • The threat of MDRP and their financial impact
  • Enforcing stricter stewardships
  • 9:10 OPENING ADDRESS: Current status and future prospects

    Richard Bax

    Richard Bax, Senior Partner, TranScrip Partners

  • Progress in R&D and drug regulation
  • What is happening in big Pharma
  • New economic models
  • What needs to be done now
  • 9:50 Extending portfolio partnerships to strengthen the antibiotic pipeline

    Christopher Houchens

    Christopher Houchens, Project Officer, BARDA

  • Ongoing and future research and development partnerships
  • BARDA’s efforts to address goals in the U.S. National Plan to Combat Antibiotic Resistant infections
  • Establishing a biopharmaceutical incubator to meet short and long term goals
  • BARDA funding opportunities
  • 10:30 Morning Coffee

    11:00 Making a material difference to healthcare

    Andrew  Cross

    Andrew Cross, Director, ACT-Surfaces Ltd

  • Two issues: HCAIs and AMR
  • The role of touch surfaces in the acquisition of infection and spread of AMR
  • Evaluation of antimicrobial efficacy
  • Evidence for copper touch surfaces and YHEC payback model
  • 11:40 Keynote Address: Fighting AMR and progressing public partnerships

    Arjon Van Hengel

    Arjon Van Hengel, Scientific Officer, European Commission

  • How is R&D being supported in a practical sense?
  • State of play of the EU action plan on AMR
  •  

    12:20 Networking Lunch

    13:20 A Global Health R&D Approach to Innovation, Conservation, and Access to New Antibiotic Treatments

    Jean-Pierre Paccaud

    Jean-Pierre Paccaud, Director of Business Development and Legal , Drugs for Neglected Diseases initiative (DNDi)
    View Bio

  • A Product Development Partnership to foster new antibiotic treatments and their responsible use
  • Making the best of what we have: Short-term approaches to combinations and reformulations of antibiotics
  • Filling gaps in upstream research: High-risk innovation beyond traditional drug discovery
  • The role of product development in testing models for conservation and access for all
  • 14:00 New insights of pathogen –host interactions and EU project - INFECT

    Anna Norrby-Teglund

    Anna Norrby-Teglund, Professor, Head of Center for Infectious Medicine, Karolinska Institutet

  • Systems medicine approach to understand pathogenic mechanisms
  • New in vitro models to understand drug resistance at the tissue site of infection
  • Accelerating drug development and diagnostic tools through INFECT
  • 14:40 Developing an antibiotic with potential for use in multiple therapeutic indications

    Prabhavathi Fernandes

    Prabhavathi Fernandes, President and Chief Executive Officer, Cempra Pharmaceuticals

  • Case study: Stage 3 clinical update outcomes and response
  • International collaboration for successful worldwide commercialisation
  • 15:20 Afternoon Tea

    15:50 Monoclonal antibody-based approaches to fight severe bacterial infections

    Eszter Nagy

    Eszter Nagy, Co-founder, President and CSO, Arsanis Biosciences

  • New paradigm to prevent and treat severe Staphyloccocus aureus infections
  • mAb products targeting MDR Gram negative infections
  • Companion diagnostics for introduction of targeted therapies and support MDR infectious disease control
  • 16:30 New business models for antibiotics: where are we now?

    Jorge Mestre-Ferrandiz

    Jorge Mestre-Ferrandiz, Director, Office of Health Economics (OHE)

    • Economic challenges – is there a need for a new business model?
    • Addressing the challenges – what could be the new business model?
    • On-going initiatives
    • Conclusions

    17:10 Rapid diagnostic tools

    Sam Whitehouse

    Sam Whitehouse, Chief Operating Officer, QuantuMDX Group

  • Advances in molecular diagnostic devices: Sample preparation and PCR 
  • Case study: Rapid diagnosis of drug-resistant forms of TB
  • Optimising speed and accuracy for rapid detection
  • Sample to result processes – fluidics and microfluidics
  • 17:50 Panel discussion: Tackling the major bottlenecks that hinder development of new antibacterial drugs

    Richard Bax

    Richard Bax, Senior Partner, TranScrip Partners

    Prabhavathi Fernandes

    Prabhavathi Fernandes, President and Chief Executive Officer, Cempra Pharmaceuticals

    Andrew  Cross

    Andrew Cross, Director, ACT-Surfaces Ltd

    Jean de Gunzburg

    Jean de Gunzburg, Chief Scientific Officer, Da Volterra

    Conrad Lichenstein

    Conrad Lichenstein, Chief Scientific Officer, Nemesis Bioscience

    Jean-Pierre Paccaud

    Jean-Pierre Paccaud, Director of Business Development and Legal , Drugs for Neglected Diseases initiative (DNDi)
    View Bio

  • Sample preparation, bottle necks in work flows
  • True point of care – Field based (not laboratory) testing
  • Multifaceted infection control programs and cost efficiency
  • Is the biotech sector the forgotten partner in developing new treatments for AMR?
  • Regulatory environment for non-traditional therapies: is a new paradigm needed?
  • Racing “The Red Queen”: How can we win the arms race?
  • Is giving taxpayer money to pharmaceutical companies the best way of stimulating the development of new anti-infectives
  • 18:30 Chairman’s Closing Remarks and Close of Day One

    Richard Bax

    Richard Bax, Senior Partner, TranScrip Partners

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Lloyd Czaplewski

    Lloyd Czaplewski, Director, Chemical Biology Ventures

    9:10 OPENING ADDRESS: What if there are no new antibiotics?

    Lloyd Czaplewski

    Lloyd Czaplewski, Director, Chemical Biology Ventures

  • Highlights of a review into the alternatives to antibiotics 
  • What can we expect within the next 10 years and how much will it cost? 
  • Why antimicrobial resistance must become a BIG science
  • 9:50 Fighting multi-drug resistant gram-negative infections

    Ankit Mahadevia

    Ankit Mahadevia, President and CEO, Spero Therapeutics

  • Development of NCE’s and combination methods that successfully penetrate the outer bacterial membrane
  • Strategic collaborations that have strengthened product pipeline
  • HTS and characterization of MvfR inhibitors and correlating clearance times of resistant strains with potent inhibitors
  • 10:30 Morning Coffee

    11:00 Antibiotic Resurrection: Taking the Path of Least Resistance

    Conrad Lichenstein

    Conrad Lichenstein, Chief Scientific Officer, Nemesis Bioscience

  • Achieving antibiotic sensitivity and resistance prevention
  • Nemesis Symbiotics: Delivery options for companion therapeutic
  • Clinical applications
  • 11:40 Building a pipeline and framework for anti-microbial drugs

    David Cook

    David Cook, Chief Scientific Officer , Blueberry Therapeutics Ltd.

    • Are their opportunities beyond small molecule antibiotics?
    • Building partnerships and collaborations to drive innovation
    • Challenges
    • Economics: the elephant in the room?

    12:20 Networking Lunch

    13:20 Clinical development of broad- spectrum anti-infective treatment drugs

    Jean de Gunzburg

    Jean de Gunzburg, Chief Scientific Officer, Da Volterra

  • Protecting the human microbiome – what do we know? New frontiers microbiome profiling
  • Narrow spectrum vs broad spectrum antibiotics on the microbiome 
  • Pre-clinical to clinical trial evaluation
  • 14:00 Determining preclinical PK/PD relationships for faster and accurate drug development

    William  Hope

    William Hope , Professor of Therapeutics and Infectious Diseases, University Of Liverpool

  • Efficiently modelling PK and PD for optimising dosage requirements of new and existing drugs
  • Regulatory recommendations of PK/PD relationships for antibacterial agents
  • Preclinical models of PK/PD results and human translatability
  • Individualised treatment and controlling extreme variability
  • 14:40 Antimicrobial peptides as viable alternatives

    Steve Boakes

    Steve Boakes, Head of Microbiology, Cantab Anti-infectives

  • Pros and Cons of antimicrobial peptides
  • Current pipeline
  • Cantab Anti-infectives experience with lantibiotics and polymyxins.
  • 15:20 Afternoon Tea

    15:50 The use of combination antibiotic therapy

    William J. Weiss

    William J. Weiss, Director of Pre-Clinical Services, University of North Texas Health Science Center

  • History of antibiotic combinations
  • Rationale for combination therapy
  • Advantages / Disadvantage of combining antibiotics
  • Testing regimens for combination therapy
  • 16:30 Hyperbaric Oxygen Treatment as an adjunctive treatment to infectious diseases and its synergistic effects

    Ole Hyldegaard

    Ole Hyldegaard, Medical Director, Associate Professor , University Hospital of Copenhagen

  • Mechanisms of HBO2 therapy in underpinning improved immunity and increased antibiotic activity
  • A retrospective analysis of patients who received HBO treatment and outcomes
  • Synergistic effects to improve clinical outcomes in patients post-surgery
  • 17:10 Microbiota host interactions as a starting point for antimicrobial strategies

    Frank Schuren

    Frank Schuren, Senior Scientist , TNO Pharma

  • Experimental microbiota platforms
  • Next generation sequencing
  • Analyzing AMR development through metagenomic
  • Host pathogen/microbiome interactions
  • 17:50 Chairman’s Closing Remarks and Close of Day Two

    Lloyd Czaplewski

    Lloyd Czaplewski, Director, Chemical Biology Ventures

    +

    FEATURED SPEAKERS

    Ankit Mahadevia

    Ankit Mahadevia

    President and CEO, Spero Therapeutics
    Anna Norrby-Teglund

    Anna Norrby-Teglund

    Professor, Head of Center for Infectious Medicine, Karolinska Institutet
    Conrad Lichenstein

    Conrad Lichenstein

    Chief Scientific Officer, Nemesis Bioscience
    Eszter Nagy

    Eszter Nagy

    Co-founder, President and CSO, Arsanis Biosciences
    Jean de Gunzburg

    Jean de Gunzburg

    Chief Scientific Officer, Da Volterra
    Jean-Pierre Paccaud

    Jean-Pierre Paccaud

    Director of Business Development and Legal , Drugs for Neglected Diseases initiative (DNDi)
    Prabhavathi Fernandes

    Prabhavathi Fernandes

    President and Chief Executive Officer, Cempra Pharmaceuticals
    Richard Bax

    Richard Bax

    Senior Partner, TranScrip Partners
    William J. Weiss

    William J. Weiss

    Director of Pre-Clinical Services, University of North Texas Health Science Center

    Andrew Cross

    Director, ACT-Surfaces Ltd
    Andrew  Cross

    Ankit Mahadevia

    President and CEO, Spero Therapeutics
    Ankit Mahadevia

    Anna Norrby-Teglund

    Professor, Head of Center for Infectious Medicine, Karolinska Institutet
    Anna Norrby-Teglund

    Arjon Van Hengel

    Scientific Officer, European Commission
    Arjon Van Hengel

    Christopher Houchens

    Project Officer, BARDA
    Christopher Houchens

    Conrad Lichenstein

    Chief Scientific Officer, Nemesis Bioscience
    Conrad Lichenstein

    David Cook

    Chief Scientific Officer , Blueberry Therapeutics Ltd.
    David Cook

    Eszter Nagy

    Co-founder, President and CSO, Arsanis Biosciences
    Eszter Nagy

    Frank Schuren

    Senior Scientist , TNO Pharma
    Frank Schuren

    Jean de Gunzburg

    Chief Scientific Officer, Da Volterra
    Jean de Gunzburg

    Jean-Pierre Paccaud

    Director of Business Development and Legal , Drugs for Neglected Diseases initiative (DNDi)
    Jean-Pierre Paccaud

    Dr. Paccaud is responsible for DNDi’s business development activities, including opportunity identification, contract structure and negotiations, and alliance management. Prior to joining DNDi, he served as Head of Business Development for R&D products at OM Pharma.

    Dr. Paccaud also notably founded and led Athelas SA, a startup company active in the field of anti-bacterial drug discovery, until its merger with Merlion Pharmaceuticals. Before taking on entrepreneurial challenges in industry, Dr. Paccaud spent more than 15 years in academia, working in immunology, diabetes, and cell biology.

    Trained as a molecular and cellular biologist, Jean-Pierre Paccaud completed his post-doctoral studies at the University of California at Berkeley (R. Schekman’s lab) , and earned his PhD at the University of Geneva School of Medicine.
     

    Jorge Mestre-Ferrandiz

    Director, Office of Health Economics (OHE)
    Jorge Mestre-Ferrandiz

    Lloyd Czaplewski

    Director, Chemical Biology Ventures
    Lloyd Czaplewski

    Ole Hyldegaard

    Medical Director, Associate Professor , University Hospital of Copenhagen
    Ole Hyldegaard

    Prabhavathi Fernandes

    President and Chief Executive Officer, Cempra Pharmaceuticals
    Prabhavathi Fernandes

    Richard Bax

    Senior Partner, TranScrip Partners
    Richard Bax

    Sam Whitehouse

    Chief Operating Officer, QuantuMDX Group
    Sam Whitehouse

    Steve Boakes

    Head of Microbiology, Cantab Anti-infectives
    Steve Boakes

    William Hope

    Professor of Therapeutics and Infectious Diseases, University Of Liverpool
    William  Hope

    William J. Weiss

    Director of Pre-Clinical Services, University of North Texas Health Science Center
    William J. Weiss

    Sponsors and Exhibitors

    Official Publication

    Supporters

    VENUE

    Holiday Inn Kensington Forum

    97 Cromwell Road , London, United Kingdom

    Holiday Inn Kensington Forum is perfectly situated in one of London’s most luxurious and beautiful areas within South Kensington. 

    The hotel is just 2 minutes walk from Gloucester Road tube station for convenient travel to Hyde Park, London Eye, Tower Bridge plus more of London’s top attractions. There are also easy and direct links to some major transport hubs including Victoria, Kings Cross St Pancras, Paddington and Heathrow. 

    This distinctive hotel in south London has so much to offer to make all guests really feel at home. The latest Holiday Inn relaunch is not just about the new look and feel for the hotel but to offer guests more benefits during their stay including a pillow menu for extra comfort during their sleep and a curved shower rail for more spacious feel. 

    In addition to our 906 rooms, all business guests can take advantage of our meeting and conference facilities including High Speed Internet Access and unlimited Starbucks coffee at The Academy. Our hotel’s professional event planners are on board to help take the hard work and stress away from planning your next event. 

    So whether you in London on business or pleasure, make the Holiday Inn London Kensington Forum your first choice of hotel and book your accommodation for our lowest internet rate guarantee. 

    HOTEL BOOKING FORM

    Preliminary List of Attendees: Superbugs & Superdrugs 2016

    Download

    An Interview with BARDA

    Download

    Quick Fire Q&A with Antibiotic Developer, Dr. Prabhavathi Fernandes

    Download

    A Message from the Superbugs Chairing Board

    Download

    Sponsors and Exhibitors


    Fidelta

    Sponsors and Exhibitors
    http://www.fidelta.eu/

    Fidelta, a Croatian based CRO, offering extensive integrated drug discovery services, has over 20 years’ experience in anti-infective drug discovery. By combining in vitro and ex vivo assays with in vivo models of infection, safety ADME and PK studies, compounds can be expertly profiled to further enhance discovery programs.

    Media Partners


    International Journal of Risk Assessment and Management

    Official Publication
    http://www.inderscience.com/ijram

    IJRAM is an interdisciplinary and refereed journal that provides cross learning between: • Different business and economics, as well as scientific and technological, disciplines • Energy industries, environmental and ecological systems • Safety, public health and medical services • Software services, reliability and safety


    Int. J. of Bioinformatics Research and Applications

    Official Publication
    http://www.inderscience.com/ijbra

    Bioinformatics is an interdisciplinary research field that combines biology, computer science, mathematics and statistics into a broad-based field that will have profound impacts on all fields of biology. The emphasis of IJBRA is on basic bioinformatics research methods, tool development, performance evaluation and their applications in biology. IJBRA addresses the most innovative developments, research issues and solutions in bioinformatics and computational biology and their applications.


    Int. J. of Biotechnology

    Official Publication
    http://www.inderscience.com/ijbt

    IJBT provides an international forum and refereed authoritative source of information in the field of Biotechnology and Biotechnics, with emphasis on management and economics, as well as the political and social issues. It aims to disseminate knowledge, provide a learned reference in the field, and establish channels of communication between academic and research experts, policy makers and executives in industry, commerce and investment institutions.

    Media Partners


    Biocompare

    Supporters
    http://www.biocompare.com

    Biocompare is the most comprehensive, in-depth, and objective website for life science product information. Thousands of scientists use Biocompare daily to quickly find the right product for their experiments rather than looking through multiple print catalogs. Visit Biocompare to find the products you need, stay informed of new technologies, read product reviews, watch product videos, and keep up-to-date on life science news. Visit: www.biocompare.com


    GenomeWeb

    Supporters
    http://www.genomeweb.com

    GenomeWeb LLC is an independent, privately-held online and print publisher based in New York. Since 1997, GenomeWeb has served the global community of scientists, technology professionals, and executives who use and develop the latest advanced tools in molecular biology research and molecular diagnostics.

    GenomeWeb’s editorial mission is to serve readers with exclusive, in-depth coverage of the technology, institutions, and scientists that make up the worldwide research enterprise of molecular biology. We operate the largest online news organization focused on advanced research tools in genomics, proteomics, and bioinformatics.

    GenomeWeb readers can be found in major biopharmaceutical companies, top research universities, biomedical institutes, and government laboratories.


    Bioscreening

    Supporters
    http://www.bioscreening.com



    SelectScience

    Supporters
    http://www.selectscience.net/register?utm_source=Media-Partner&utm_medium=Website&utm_campaign=SMI

    SelectScience is an independent, online information resource for the worldwide scientific community, and the home of trusted information for laboratory scientists. Discover the latest drug discovery and development technologies, products and techniques with product reviews, videos, application notes and news articles. Become a member for free today.


    Absave

    Supporters
    http://www.absave.com

    Absave.com is the leading savings website for Antibodies and Immunological Products. Search our extensive database of Antibodies, Kits, Proteins & Peptides, Reagents, etc. to find the best savings!


    Drug Discovery Today

    Supporters
    http://www.drugdiscoverytoday.com/

    Drug Discovery Today is one of the most cited review journals in the field of drug discovery, with an impact factor of 6.422.
    Drug Discovery Today will benefit your research by helping to keep you up-to-date with all of the fast-moving and emerging topics in drug discovery. Each issue is packed full of the latest research news, peer-reviewed articles and comment and opinion from leading research scientists.


    Farmavita

    Supporters
    http://www.farmavita.net/

    Farmavita Net is professional community and network of pharmaceutical licensing and business development executives, innovators and researchers
    Farmavita.Net is the pharmaceutical licensing, technology transfer and regulatory affairs network. We are managing the marketplace of offers and demand for pharmaceutical Dossiers, know-how and technologies. Members of Farmavita.Net network usually find a number of attractive solutions for business development, alliances, joint ventures, co-development and co-marketing of pharmaceutical products. Farmavita.Net is not just a pure Internet portal. We manage a number of regional associates. We are connecting the dynamic network of few hundreds members / pharmaceutical companies interested in license-in and license-out opportunities.


    Biosave

    Supporters
    http://www.Biosave.com

    Biosave.com brings together the best Life Science promotions, product releases, featured products, publications, videos and events from 100’s of leading Life Science suppliers. Updated 24 hours a day, Biosave is constantly uploading special promotions and exciting product news that you won’t find anywhere else. Our goal is to provide our users with the most exclusive product information to help reach that all important purchasing decision.


    Swiss Biotech Association

    Supporters
    http://www.swissbiotech.org/

    The Swiss Biotech Association (SBA) is the national industry association for biotechnology, including pharmaceuticals, diagnostics, agriculture, food, cosmetics, environmental biotechnology, and specialty chemicals. Members are companies active in modern biotechnology, such as R&D, Production, Marketing and Sales, Finance, Services and Consulting. SBA provides a networking platform for Life Science clusters, academic and federal institutions the like. Founded in March 1998, the Association grows steadily.


    British Pharmacological Society

    Supporters
    http://www.bps.ac.uk

    The British Pharmacological Society (BPS) is the primary UK learned society concerned with research into drugs and the way they work. Our members work in academia, industry, regulatory agencies and the health services, and many are medically qualified. The Society covers the whole spectrum of pharmacology, including laboratory, clinical, and toxicological aspects. Clinical pharmacology is the medical speciality dedicated to promoting safe and effective use of medicines for patient benefit. Clinical pharmacologists work as consultants in the NHS and many hold prominent positions in UK Universities.


    PMR

    Supporters
    http://www.pmrcorporate.com

    PMR (www.pmrcorporate.com) is a British-American company providing market information, advice and services to international businesses interested in Central and Eastern European countries as well as other emerging markets. PMR's key areas of operation include business publications (through PMR Publications), consultancy (through PMR Consulting) and market research (through PMR Research ). Being present on the market since 1995, offering high international standards in projects and publications, as well as providing one of the most frequently visited and top-ranked websites, PMR is one of the largest companies of its type in the region.


    CanBiotech

    Supporters
    http://www.canbiotech.com

    CanBiotech - A Portal and B2B Outsourcing Marketplace for the Biotech and Pharmaceutical Industry. The Marketplace features the Outsourcing Services Showcase; the Portal features our biopharmaceutical and venture capital directories and databases. Publications include the BioMedical Outsourcing Report and the Bio Outsourcing Asia© Publication.


    Pharmavision

    Supporters
    http://www.pharmavision.co.uk

    PharmaVision offers a consultancy service providing independent pharmaceutical thematic research to the healthcare industry, the investment community and competitive intelligence specialists. We perform due diligence research and provide expert commentary in healthcare. Our reports combine scientific analysis in drug delivery, R&D technologies and pharmaceutical products including patient modelling, product/technology forecasts and market trends evaluation.


    PharmaVOICE

    Supporters
    http://www.pharmavoice.com

    PharmaVOICE magazine, and its supporting VIEW publications, provide commentary about the challenges and trends impacting the life-sciences industry, covering a range of issues from molecule through market. PharmaVOICE's more than 41,000 U.S.-based subscribers are also kept abreast of the latest trends through additional media resources, including WebSeminars, Podcasts, Videocasts, and White Papers.


    Labhoo

    Supporters
    http://www.labhoo.com



    Drug Development Technology

    Supporters
    http://www.drugdevelopment-technology.com

    Drugdevelopment-technology.com covers every aspect of the drug development and research process, from conception to pre-FDA approval. Our global network of journalists updates the site with the latest and most significant industry developments. This coverage allows us to provide everyone - from senior management through to research and QA staff – with in-depth reviews of the latest projects, advance notice of new product releases and analysis of the latest procedural and legislative developments.


    Pharmacircle

    Supporters
    http://www.pharmacircle.com

    PharmaCircle is an innovative knowledge management company serving the current and future global leaders in the Pharmaceutical and Biotechnology related industries. PharmaCircle is a one stop information and analysis source for pipeline, products, clinical trials, drug delivery technologies, deals and acquisitions, company financials, venture capital investments, product sales, pharmaceutical services, news, patents and more….


    Mednous

    Supporters
    http://www.MedNous.com

    MedNous is a print publication and website about medical innovation in Europe. It carries exclusive interviews with companies that are at the forefront of medical technology, as well as contributor articles from prominent practitioners. Our mission is to identify significant advances in medicine and to explain how this innovation is being commercialised. In doing so, we talk to venture capitalists about what products and platforms they are supporting. We report on how regulators cope with the accelerating pace of innovation. And we regularly cover the latest developments in the discovery and development of new medical concepts in the area of antibodies, vaccines, small molecules, regenerative medicine and nanomedicines. MedNous combines the English word for medicine with the Greek word for intellect. And those with nous are readers of our publication. Visit our website: www.mednous.com


    Technology Networks

    Supporters
    http://www.technologynetworks.com

    Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com


    Bentham Science

    Supporters
    http://www.benthamscience.com/

    Bentham Science Publishers is a major STM journal publisher of 116 titles and 200 plus open access journals and print/online book series (Bentham eBooks). Bentham Science answers the information needs of the pharmaceutical and biomedical research community. Leading journals include Current Drug Metabolism (Impact Factor 5.113) and Current Medicinal Chemistry (Impact Factor 4.859): FREE online journals and information: www.benthamscience.com


    pharmaphorum

    Supporters
    http://www.pharmaphorum.com

    pharmaphorum drives innovation within the pharmaceutical industry, by bringing healthcare together through a suite of media services that help produce and disseminate thought leadership, combined with an online platform for communicating messages to a global audience.Visit www.pharmaphorum.com


    Labsave

    Supporters
    http://www.labsave.com

    Labsave is the leading savings website for Laboratory Equipment and Lab Supplies. We work closely with the top suppliers in the world to bring you the best products at the most competitive prices. We are constantly striving to secure the biggest and most exclusive offers that you won’t find anywhere else! http://www.labsave.com/


    Lab Bulletin

    Supporters
    http://www.labbulletin.com

    Lab Bulletin is a free online resource for scientists and laboratory professionals where you can catch up on the latest news for laboratory products and services. You will find an extensive directory of laboratory suppliers and manufacturers enabling you to contact companies quickly and easily to request further information. Lab Bulletin also publishes four free monthly E-Newsletters keeping you up-to-date with all of the latest laboratory products and industry news directly to your inbox. We have dedicated E-Newsletters for Chromatography and Spectroscopy, Microscopy and Image Analysis, weekly Industry News updates and our monthly Lab Bulletin E-Newsletter sent out to over 29,000 readers worldwide. To request your free copy click here


    Pharmalicensing

    Supporters
    http://www.pharmalicensing.com

    Pharmalicensing (www.pharmalicensing.com) is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide. Actively supporting all forms of partnering and in- and out-licensing activities, Pharmalicensing utilizes the unique Partnering Search service and its global network of industry experts to enable companies to identify and engage with appropriate partners around the world. Pharmalicensing, and its sister service Medical Device Licensing (www.medicaldevicelicensingcom) are actively utilized by over 200,000 industry professionals each month. Pharmalicensing is a division of IP Technology Exchange, Inc.


    Inderscience Publishers

    Supporters
    http://www.inderscience.com

    Inderscience is a dynamic, leading, independent journal publisher. The company disseminates the latest research across the broad fields of science, engineering and technology; management, public and business administration; environment, ecological economics and sustainable development; computing, ICT and internet/web services, and related areas. Inderscience offers over 35 years' experience in publishing and has succeeded in building a substantial collection approaching 400 high-quality peer-reviewed international research journals in both online and print formats. We offer a variety of ways to keep up-to-date with the latest published leading-edge research while our online collection represents a fully-searchable digital archive of around 60,000 articles.


    Conference-Service.com

    Supporters
    http://www.conference-service.com/

    COMS is a web application for managing delegate registration, payment, paper submission and paper review. Written in Perl and C, with a MySQL database at the back end, it is a comprehensive and powerful, yet easy to use solution for online conference management.


    Gate2Biotech

    Supporters
    http://www.gate2biotech.com

    Gate2Biotech is a portal that unites biotechnological community in Central Europe. It covers all the news in the field of biotechnology. Thanks to the the portal the companies engaged in the field can easily search for research institutions and other partners to solve technical problems they are facing and here they can also present their services offer to potential partners from the Czech Republic and abroad. Gate2Biotech portal serves as a bridge connecting scientific and commercial sector. It incorporates offices and support organizations dedicated to promoting transfer of innovative technologies into a unified communication platform of Czech and international biotechnologies. As a mediator of information it draws attention to biotechnologies and support of their application and transfer into practice. It also functions as a tool for encouraging non-professionals (especially scientists and students) towards innovative business or applied research.


    The Royal Society of Chemistry

    Supporters
    http://www.rsc.org/

    The Royal Society of Chemistry is an international publishing and knowledge business which is the UK’s professional body for chemical scientists; supporting and representing members and bringing together scientists from all over the world. It is a not-for-profit organisation and has an ambitious international vision for the future. It also advises governments on policy and promotes the talent, information and ideas that lead to great advances in science.


    Pharmaceutical Technology

    Supporters
    http://www.pharmaceutical-technology.com

    Pharmaceutical-technology.com is the only website focusing specifically on issues relevant to pharmaceutical professionals working with technology, be it development, engineering, IT or production. Pharmaceutical-technology.com brings you the latest in industry projects and updates, along with the news, views and trends that leading professionals – from senior executives to manufacturing managers and heads of procurement – require to stay on top of their field.


    Drug Discovery World

    Supporters
    http://www.ddw-online.com

    For over a decade DDW has continued to be the ‘must read’ journal within the DD&D Arena. DDW is recognised for voicing the opinions of some of the Industry’s leading luminaries and has become a recognised platform for Industry Gurus to debate some of the more challenging technological and business issues facing the the life science industry. DDW adheres to the maxim..... ‘Turning Science into Business’ DDW examines the advances in new technologies and the associated implications within the context of developing new and efficacious therapeutics. DDW is distinguishable in that it reaches out to a global audience at both bench and boardroom level, allowing both camps to profit from the uncomplicated style of editorial but at the same time challenges our readers to look at new ways to overcome discovery bottlenecks, embrace nascent technologies and build next generation technology platforms.


    Pharmiweb

    Supporters
    http://www.pharmiweb.com

    Established in October 2003, PharmiWeb Solutions is an energetic, innovative provider of web-based solutions for the pharmaceutical sector, with customers such as AstraZeneca, Roche, Servier Laboratories, and Merck With solutions in three key areas: Online Publishing, e-Business and Mobile Computing, we deliver connectivity – between people and applications – unlocking islands of data and knowledge. We own some of the sector’s most innovative Online Publications: PharmiWeb.com, HospitalPharma.com and Detail-Direct.com. We are actively developing solutions for Mobile Computing platforms. For example, our PharmiTabTM e-pharmacy solution runs real-time patient data and prescribing transactions in a busy hospital environment, on a TabletPC, wireless client/server platform. e-Business solutions range from e-Detailing, to Online Market Research, all designed to increase reach, increase sales, and to reduce administration and costs.

    SAVE TO


    Outlook Calendar  OUTLOOK CALENDAR
    Google Calendar  GOOGLE CALENDAR
    ICal Calendar  ICAL CALENDAR
    Yahoo! Calendar  YAHOO! CALENDAR

    Holiday Inn Kensington Forum

    97 Cromwell Road
    London SW7 4DN
    United Kingdom

    Holiday Inn Kensington Forum

    Holiday Inn Kensington Forum is perfectly situated in one of London’s most luxurious and beautiful areas within South Kensington. 

    The hotel is just 2 minutes walk from Gloucester Road tube station for convenient travel to Hyde Park, London Eye, Tower Bridge plus more of London’s top attractions. There are also easy and direct links to some major transport hubs including Victoria, Kings Cross St Pancras, Paddington and Heathrow. 

    This distinctive hotel in south London has so much to offer to make all guests really feel at home. The latest Holiday Inn relaunch is not just about the new look and feel for the hotel but to offer guests more benefits during their stay including a pillow menu for extra comfort during their sleep and a curved shower rail for more spacious feel. 

    In addition to our 906 rooms, all business guests can take advantage of our meeting and conference facilities including High Speed Internet Access and unlimited Starbucks coffee at The Academy. Our hotel’s professional event planners are on board to help take the hard work and stress away from planning your next event. 

    So whether you in London on business or pleasure, make the Holiday Inn London Kensington Forum your first choice of hotel and book your accommodation for our lowest internet rate guarantee. 

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 2nd Floor South, Harling House, 47-51 Great Suffolk Street, London, SE1 0BS, United Kingdom, Link to Map
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.